Methylenetetrahydrofolate Reductase (MTHFR) C677T polymorphism is associated with hypertension depending on ethnic and geographic region. Several studies found that the affordable and widely available riboflavin or vitamin B2 as a cofactor of MTHFR could lower blood pressure in patients with MTHFR variants. The benefits of risk stratification and therapeutic potential made it interesting to be studied. No study of MTHFR C677T polymorphism on hypertension is available in Indonesia.
This study sought to determine the association of MTHFR C677T gene polymorphism and hypertension in rural Sundanese population of Gunung Sari Village, Bogor-Indonesia.
A total of 415 subjects consisting of 213 hypertensive subjects and 202 non-hypertensive subjects as a control group were enrolled in this case-control study. The genotypes of the MTHFR C677T were determined by a TaqMan assay.
There was a significant difference of MTHFR C677T polymorphism between hypertensive group and control group; 62,9% CC; 34,3% CT; 2,8% TT vs 77,7% CC; 20,8% CT; 1,5% TT with p value of 0,004; and mutant (TT and CT) vs wild type genotype (CC) with p value of 0,001 respectively. After adjustment of age, body mass index, waist circumference, and diabetes mellitus, there was an association between MTHFR C677T polymorphism with hypertension (OR 2,1; 95% CI 1,3–3,5)
There is an association between MTHFR C677T gene polymorphism and hypertension in rural Sundanese population of Gunung Sari Village, Bogor-Indonesia.
Department of Cardiology and Vascular Medicine, Universitas Indonesia, National Cardiovascular Center, Jakarta, Indonesia